- Athersys (NASDAQ:ATHX) has entered into an agreement with HEALIOS K.K. to expand their collaboration into additional therapeutic areas.
- Healios receives rights to develop and commercialize additional indications and Athersys receives $20M in license fees, milestones payments of up to ~$360M as well as tiered double-digit royalties on MultiStem therapies developed for ARDS, and single-digit royalties for other licensed products.
- Under the terms of the agreement, Healios will also receive a credit of $10M and a right of first negotiation to broaden the field and territory related to MultiStem cells used in combination with iPSC-derived cells. It has been granted a right of first negotiation regarding an exclusive option for a license to develop and commercialize MultiStem therapy for certain indications in China, and the potential inclusion of an additional indication to the Japan license.
- Shares of ATHX are up 16% premarket on modest volume.
- Previously: Healios and Athersys expand MultiStem partnership (March 13)
- Now read: Athersys/Healios Warrant Structure Bullish For Athersys Shares
Original article